Times are hard all over, as a tally of 2002 health care financings makes plain: as of late November, just 353 private financings had been finalized across all sectors—biotechnology and pharmaceuticals, diagnostics and devices—down from 438 private financings completed in 2001, and way down from the 504 finalized in 2000. A cursory analysis shows that investors favored companies that offered them the most certainty of a quick return.
The biggest stacks of private money went to start-ups with the potential to bring numerous products to market. Spin-offs attracted...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?